90741-36-9

Upstream product

• 90741-33-6 (2S)-1-benzyl-(E)-5-<(methoxycarbonyl)methylidene>proline tert-butyl ester 
• 56-86-0 L-glutamic acid 
• 100-52-7 benzaldehyde 
• 77539-18-5 (S)-(+)-2-benzylamino glutaric acid 
• 38854-94-3 N-benzyl-L-pyroglutamic acid 
• 90741-27-8 (S)-tert-butyl 1-benzyl-5-oxopyrrolidine-2-carboxylate 
• 90741-31-4 (S)-N-benzyl-5-thioxoproline tert-butyl ester 

Downstream Products

• 90741-38-1 (2S)-cis-1-benzyl-5-((methoxycarbonyl)methyl)proline 
• 90741-37-0 (2S)-cis-1-benzyl-5-(carboxymethyl)proline tert-butyl ester 
• 90741-40-5 tert-butyl (2R,5R)-1-benzyl-5-(2-hydroxyethyl)pyrrolidine-2-carboxylate 
• 113472-56-3 (2S)-cis-1-(benzyloxycarbonyl)-5-vinylproline tert-butyl ester 
• 182137-38-8 (2S,5R)-5-(2-Bromo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 178813-40-6 (2S,5R)-5-(2-Hydroxy-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 182137-69-5 (2S,5R)-5-(2-Phenylselanyl-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 182137-68-4 (2S,5R)-5-(2-Methanesulfonyloxy-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 182138-57-4 (1S,3S,4R)-3-Triethylsilanyloxy-7-aza-bicyclo[2.2.1]heptane-1,7-dicarboxylic acid 7-benzyl ester 1-tert-butyl ester 
• 182266-45-1 (2S,5R)-(R)-5-Oxiranyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 182137-71-9 (2S,5R)-(S)-5-Oxiranyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 182137-73-1 (2S,5R)-5-((S)-2-Bromo-1-triethylsilanyloxy-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 182266-46-2 (2S,5R)-5-((R)-2-Bromo-1-triethylsilanyloxy-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 90762-72-4 (2R)-1-benzyl-2-((methoxycarbonyl)methyl)pyrrolidine 

Relevant academic research and scientific papers

A the non-peptide class perishes weakly inhibiting protein antagonists and its synthetic method and application (by machine translation)

This invention discloses a kind of the non-peptide class perishes weakly inhibiting protein antagonist and method for preparing the same and application, which aims to provide a better anticancer effect with the non-peptide class perishes weakly inhibitin

Inhibitors of α4β1 mediated cell adhesion

The present invention relates to compound of formula (I), that are potent inhibitors of α4β1mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the molecules of the present invention can be used for treating or preventing α4β1adhesion mediated conditions in a mammal such as a human. This method may comprise administering to a mammal or a human patient an effective amount of the compound or composition as explained in the present specification.

Chirospecific synthesis of conformationally constrained 7-azabicycloheptane amino acids by transannular alkylation

A new method is reported for the chirospecific preparation of optically pure 1-carboxy-7-azabicycloheptane amino acids for the generation of peptidomimetics as conformational probes. The method allows for the multigram preparation of these amino acid analogues through use of a thiolactam sulfide contraction and a transannular alkylation sequence as the key C-C bond-forming steps, starting from L-glutamic acid. The route provides access to two common intermediates, 7-(benzyloxycarbonyl)-1-carboxy-7-azabicyclo[2.2.1]-3-heptane and (1S,4R)-7-(benzyloxycarbonyl)-1-carboxy-7-azabicyclo[2.2.1]-3-heptanon e tert-butyl ester, for elaboration to symmetrical and chiral amino acid homologues, respectively. Decarboxylation of the C-1 carboxy unit of the latter intermediate also demonstrated the applicability of the method for a short, chirospecific preparation of a (+)-epibatidine intermediate, (1S,4R)-7-(tert-butyloxycarbonyl)-1-carboxy-7-azabicyclo[2.2.1]3-hepta none.

DIVERSIFIED SYNTHETIC APPROACHES TO THE CARBAPENEM ANTIBIOTICS BASED ON SYMMETRIZATION-ASYMMETRIZATION CONCEPT

cis-Fused bicyclic β-lactam compound 9, a key intermediate to cis-substituted carbapenem antibiotics, has been synthesized in optically pure form based on symmetrization-asymmetrization concept.